Researchers uncover hidden breast cancer subtype in gulf women
NCT ID NCT06125314
First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 36 times
Summary
This study reviewed medical records of over 500 women in Gulf countries with advanced breast cancer that was previously labeled as HER2-negative. Researchers re-tested old tumor samples to find out how many actually had a newer subtype called HER2-low. The goal was to better understand how common this subtype is and how it behaves, which could help guide future treatment decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Kuwait City, Kuwait
-
Research Site
Doha, Qatar
-
Research Site
Mecca, Saudi Arabia, Saudi Arabia
-
Research Site
Riyadh, Saudi Arabia
-
Research Site
Abu Dhabi, United Arab Emirates
-
Research Site
Al Ain City, United Arab Emirates
-
Research Site
Dubai, United Arab Emirates
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.